Senate Finance Committee Chair Orrin Hatch joined the mounting effort in Congress to scale back the 340B program and redefine how hospitals use their drug discounts from the program.Original Article
Hatch asks Azar to shift 340B oversight to CMS
You may also like
Ninth Circuit Upholds FDA’s Authority to Regulate...
Skinny-Label Lives to See Another Day
Bring Out Your Meds! Bring Out Your Meds!
Homeopathic Industry Group Wants Court to Exclude It...
A Reversal on Sequencing? Proposed Legislation Would...
FDA Guidance Outlines a Framework for the Evaluation...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.